NCT01850524: Phase 3 - TOURMALINE-MM2 - Oral Ixazomib + Lenalidomide/Dex Vs Placebo + Len/Dex NDMM
NCT01665794: Phase 1/2: Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With RRMM
NCT01568866: Phase 3 - Carfilzomib and Dex Vs Bortezomib & Dex for Relapsed Myeloma (ENDEAVOR)
NCT01454297: MMRF CoMMpass Study in Newly Diagnosed Multiple Myeloma - (CoMMpass)
NCT01239797: Phase 3: Lenalidomide and Dexamethasone With or Without Elotuzumab RRMM (ELOQUENT - 2)
NCT01080391: Comparing Carfilzomib, Lenalidomide & Dex (CRd) vs Lenalidomide and Dex (Rd) - ASPIRE
NCT01023308: Phase 3 - Panobinostat or Placebo With Bortezomib & Dex in Relapsed Myeloma PANORAMA-1
NCT00689936: Phase 3 - Lenalidomide+low dose dex vs Melphalan, Prednisone, Thalidomide in NDMM FIRST
NCT00609167: Phase 2: Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With NDMM
NCT00511238: Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma
NCT00473590: Phase 2 - Bevacizumab in Combination With Bortezomib in MM (AMBER)
NCT00056160 : Phase 3 - CC-5013 (lenalidomide) Dex Vs Dex Alone Previously Treated Multiple Myeloma